Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01061749 · ClinicalTrials.gov registry record · Phase 1
Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01061749: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01061749 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01061749, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This phase I clinical trial studies the safety and best dose of selumetinib and cixutumumab in treating patients with advanced solid malignancies. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry \[cancer/tumor\]-killing substances to them.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Selumetinib
- OTHER Pharmacological Study
- BIOLOGICAL Cixutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01061749
The ClinicalTrials.gov registry entry for NCT01061749 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01061749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01061749 about?
NCT01061749 is a clinical study titled "Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies". This phase I clinical trial studies the safety and best dose of selumetinib and cixutumumab in treating patients with advanced solid malignancies. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can bl...
What is the current status of trial NCT01061749?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-11. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01061749?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Selumetinib (DRUG), Pharmacological Study (OTHER), Cixutumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01061749?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.